Impact of topoisomerase IIα overexpression in the primary colon tumor on the prognosis of metastatic colorectal cancer

Impact of topoisomerase IIα overexpression in the primary colon tumor on the prognosis of metastatic colorectal cancer

Background. The evaluation of clinical and morphological characteristics is not sufficient to predict the prognosis of metastatic colorectal cancer (mRCC). Tumor aggressiveness may vary significantly even in patients with similar clinical and morphological disease characteristics. These differences...

Full description

Bibliographic Details
Main Authors:	A. D. Darenskaya, N. V. Dobrova, E. V. Stepanova
Format:	Article
Language:	Russian
Published:	“ABV-press” Publishing house”, LLC 2018-11-01
Series:	Тазовая хирургия и онкология
Subjects:	topoisomerase iiα metastatic colorectal cancer first-line treatment chemotherapy oxaliplatin capecitabine molecular biomarkers
Online Access:	https://ok.abvpress.ru/jour/article/view/257

Similar Items

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy
by: Yue Liu, et al.
Published: (2022-05-01)

Prognostic value of Bax expression in the primary colon tumor of patients with metastatic colorectal cancer receiving first-line treatment with a triple combination of irinotecan + oxaliplatin + long-term infusion of 5-fluorouracil
by: A. D. Darenskaya, et al.
Published: (2019-06-01)

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study
by: Xiu Liu, et al.
Published: (2022-07-01)

Triple combination of irinotecan + oxaliplatin + 5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer: first experience with a new treatment regimen
by: A. D. Darenskaya, et al.
Published: (2018-05-01)

A Randomised Controlled Phase II Trial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer
by: Jing Lv, et al.
Published: (2012-06-01)

Results of using tegafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2018-11-01)

Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2019-12-01)

CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHES
by: N. V. Dobrova, et al.
Published: (2017-11-01)

Time-Tested Strategies in Modern Context: A Bibliometric Study of Chemotherapy’s Continued Importance in Colorectal Cancer Treatment
by: Helena Clar-Marmaneu, et al.
Published: (2023-09-01)

A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer
by: Min Shi, et al.
Published: (2020-03-01)

Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation
by: A. D. Darenskaya, et al.
Published: (2018-11-01)

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
by: Goro Nakayama, et al.
Published: (2017-04-01)

Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis
by: Bradley Ashley Gue Ong, et al.
Published: (2022-04-01)

Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
by: Renata Ferrarotto, et al.
Published: (2013-09-01)

FTORAFUR IN COMBINATION WITH OXALIPLATIN AND IRINOTECAN IN PATIENTS WITH DISSEMINATED COLORECTAL CANCER: PRELIMINARY RESULTS
by: N. V. Dobrova, et al.
Published: (2018-02-01)

A Perspective on the Role of Microbiome for Colorectal Cancer Treatment
by: Sanjna Kalasabail, et al.
Published: (2021-09-01)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
by: Akihiko Hatano, et al.
Published: (2023-11-01)

A Case of Long Partial Response to Combination Therapy of Bevacizumab and Capecitabine for Liver Metastases of Rectal Cancer
by: Atsushi Kawasaki, et al.
Published: (2011-01-01)

Acute arterial thrombosis in a colon cancer patient after administration of oxaliplatin with capecitabine chemotherapy “case report”
by: Tala Alawabdeh, et al.
Published: (2022-06-01)

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience
by: Jianhong Peng, et al.
Published: (2019-10-01)

Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine
by: Mahshid Mohammadian, et al.
Published: (2019-08-01)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
by: Hélène Bellio, et al.
Published: (2021-10-01)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
by: Chu Matsuda, et al.
Published: (2023-01-01)

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study
by: Tsunekazu Mizushima, et al.
Published: (2019-09-01)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
by: Yu S, et al.
Published: (2020-10-01)

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
by: Xue-Lian Chen, et al.
Published: (2016-04-01)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01)

Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study
by: Dellas Kathrin, et al.
Published: (2012-06-01)

Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
by: Jia X, et al.
Published: (2023-03-01)

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II
by: Huanli Xu, et al.
Published: (2016-11-01)

Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines
by: Mahshid Mohammadian, et al.
Published: (2017-01-01)

Novel 9-Benzylaminoacridine Derivatives as Dual Inhibitors of Phosphodiesterase 5 and Topoisomerase II for the Treatment of Colon Cancer
by: Lina Ammar, et al.
Published: (2023-01-01)

A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer
by: John H. Strickler, et al.
Published: (2019-11-01)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience [Corrigendum]
by: Guo Q, et al.
Published: (2020-03-01)

Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer
by: Xiao-Yin Zhao, et al.
Published: (2022-10-01)

Impacts of bevacizumab on D-dimer, fibrinogen and arteriovenous thromboembolism in the treatment of advanced colorectal cancer
by: MIAO Min, et al.
Published: (2023-09-01)

Prognostic relevance of topoisomerase II α and minichromosome maintenance protein 6 expression in colorectal cancer
by: A. Hendricks, et al.
Published: (2019-05-01)

First reported case of ANCA-associated vasculitis induced by oxaliplatin, capecitabine, and trastuzumab
by: Bengang Huo, et al.
Published: (2023-12-01)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mohammad Ali Mashhadi, et al.
Published: (2016-10-01)

Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: A retrospective analysis from a medical center
by: Yung-Chia Kuo, et al.
Published: (2014-06-01)